Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent.

Authors:
Fraser CR; Ajenjo J; Veal M; Dias GM; Chan C and 7 more

Journal:
EJNMMI Res

Publication Year: 2022

DOI:
10.1186/s13550-022-00920-z

PMCID:
PMC9375819

PMID:
35962885

View on PubMed View on PMC View Publisher
Journal Information

Full Title: EJNMMI Res

Abbreviation: EJNMMI Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Radiology, Nuclear Medicine & Medical Imaging

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Dynamic whole-body [<sup>18</sup>F]FES PET/CT increases lesion visibility in patients with metastat…
Pedersen MA; Munk OL; Dias AH and 11 more (2024) - Transparency Score: 4/6
Pharmacodynamics and biodistribution of [195mPt]cisplatin(CISSPECT®) in head and neck squamous cell…
de Roest RH; Stigter van Walsum M; van der Schilden K and 1 more (2024) - Transparency Score: 3/6
PSMA imaging as a non-invasive tool to monitor inducible gene expression in vivo.
Simunic M; Joshi JT; Merkens H and 4 more (2024) - Transparency Score: 3/6
Risk of treatment-altering haematological toxicity and its dependence on bone marrow doses in pepti…
Persson M; Hindorf C; Ardenfors O and 2 more (2024) - Transparency Score: 3/6
Spherization indices measured by resting SPECT improve risk stratification in patients with ischemi…
Zhao Y; Hu Y; Li Y and 9 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateAll animal procedures were performed in accordance with the UK Animals (Scientific Procedures) Act 1986 and ARRIVE guidelines with local ethical committee approval from the University of Oxford Biomedical Services team. No human participants were used in this study. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

Evidence found in paper:

"Funding This research was supported by MRC (MR/R01695X/1) and CRUK though the Oxford Institute for Radiation Oncology."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025